Vivid News Wave

DexCom: Fairly Priced In 2025; Why I'm Not Expecting A Share Price Comeback


DexCom: Fairly Priced In 2025; Why I'm Not Expecting A Share Price Comeback

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth. Invest alongside the model portfolio, or simply access the investment bank-grade financial models and research. I hope to see you there.

Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston BioHealth. The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, integrated financial statements, discounted cash flow analysis and market by market analysis.

Previous articleNext article

POPULAR CATEGORY

corporate

9660

tech

9208

entertainment

11991

research

5555

misc

12713

wellness

9726

athletics

12629